ADMA Biologics, Inc.
ADMA
$9.38
-$0.17-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 168.96M | 165.35M | 146.93M | 209.45M | 208.93M |
| Total Depreciation and Amortization | 7.69M | 7.97M | 8.10M | 7.99M | 7.91M |
| Total Amortization of Deferred Charges | 750.00K | 718.00K | 717.00K | 739.00K | 821.00K |
| Total Other Non-Cash Items | 26.28M | 27.88M | 34.25M | -49.86M | -58.70M |
| Change in Net Operating Assets | -66.96M | -73.60M | -139.60M | -103.35M | -82.26M |
| Cash from Operations | 136.72M | 128.32M | 50.40M | 64.97M | 76.71M |
| Capital Expenditure | -20.25M | -20.42M | -22.58M | -24.25M | -10.94M |
| Sale of Property, Plant, and Equipment | 5.00M | 5.00M | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 755.00K | 650.00K | 684.00K | -117.00K | -159.00K |
| Cash from Investing | -14.50M | -14.77M | -21.89M | -24.37M | -11.10M |
| Total Debt Issued | 200.00M | 230.00M | 105.00M | 105.00M | 30.00M |
| Total Debt Repaid | -76.88M | -106.41M | -105.94M | -135.47M | -90.00M |
| Issuance of Common Stock | 1.44M | 3.47M | 2.98M | 3.00M | 8.30M |
| Repurchase of Common Stock | -197.30M | -169.51M | -41.49M | -33.07M | -10.22M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.76M | -4.58M | -4.58M | -5.39M | -1.65M |
| Cash from Financing | -76.49M | -47.03M | -44.02M | -65.93M | -63.57M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 45.74M | 66.53M | -15.52M | -25.32M | 2.04M |